Gyre Therapeutics (GYRE) News Today $10.37 -1.03 (-9.04%) Closing price 04:00 PM EasternExtended Trading$10.86 +0.49 (+4.68%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Major Exercise Alert: Weiguo Ye Exercises Options Worth $478K At Gyre TherapeuticsMay 15, 2025 | benzinga.comGyre Therapeutics (NASDAQ:GYRE) Trading 14.3% Higher - Still a Buy?Gyre Therapeutics (NASDAQ:GYRE) Trading 14.3% Higher - Here's What HappenedMay 14, 2025 | marketbeat.comGyre Therapeutics First Quarter 2025 Earnings: EPS: US$0.031 (vs US$0.09 in 1Q 2024)May 10, 2025 | finance.yahoo.comGyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | globenewswire.comA Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To EquityMay 7, 2025 | finance.yahoo.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 5.9% - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 5.9% - Here's WhyMay 7, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Hits New 12-Month High - Still a Buy?Gyre Therapeutics (NASDAQ:GYRE) Sets New 12-Month High - Here's WhyMay 3, 2025 | marketbeat.comGyre Therapeutics (GYRE) to Release Quarterly Earnings on ThursdayGyre Therapeutics (NASDAQ:GYRE) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-gyre-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Up 5% - Time to Buy?Gyre Therapeutics (NASDAQ:GYRE) Trading 5% Higher - Should You Buy?April 30, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Up 4.7% - Time to Buy?Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 4.7% - Here's What HappenedApril 17, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Hits New 12-Month Low - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Reaches New 12-Month Low - Here's WhyApril 12, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 11.9% - What's Next?Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 11.9% - Here's What HappenedApril 11, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Up 13.3% - Here's What HappenedGyre Therapeutics (NASDAQ:GYRE) Shares Up 13.3% - Here's What HappenedApril 10, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Up 10.5% - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Trading Up 10.5% - Should You Buy?April 4, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Sets New 1-Year Low - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Hits New 1-Year Low - What's Next?April 2, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Down 12.5% - Time to Sell?Gyre Therapeutics (NASDAQ:GYRE) Shares Down 12.5% - What's Next?April 1, 2025 | marketbeat.comGyre Therapeutics announces NMPA approval for trial on pirfenidoneMarch 31, 2025 | markets.businessinsider.comGyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary ComplicationsMarch 31, 2025 | globenewswire.comGyre Therapeutics announces publication of protocol for Phase 3 trial on F351March 27, 2025 | markets.businessinsider.comWe Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) EarningsMarch 27, 2025 | finance.yahoo.comGyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational HepatologyMarch 27, 2025 | globenewswire.comGyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $20,260.00 in StockGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $10.13, for a total transaction of $20,260.00. Following the completion of the transaction, the president now directly owns 2,827,018 shares of the company's stock, valued at approximately $28,637,692.34. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.March 22, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.7% - Time to Sell?Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.7% - What's Next?March 22, 2025 | marketbeat.comGyre: Intriguing Upcoming Data Catalyst, But I'm Still On SidelinesMarch 21, 2025 | seekingalpha.comGyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 SharesGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $12.09, for a total value of $24,180.00. Following the sale, the president now directly owns 2,829,260 shares of the company's stock, valued at $34,205,753.40. This represents a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 20, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Up 10.5% - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Shares Up 10.5% - What's Next?March 20, 2025 | marketbeat.comGyre Therapeutics offers weak 2025 revenue guidanceMarch 19, 2025 | uk.investing.comGyre Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 19, 2025 | finance.yahoo.comGyre Therapeutics (GYRE) Receives a Buy from Noble FinancialMarch 19, 2025 | markets.businessinsider.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Down on Disappointing EarningsGyre Therapeutics (NASDAQ:GYRE) Shares Gap Down After Earnings MissMarch 19, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPSGyre Therapeutics (NASDAQ:GYRE - Get Free Report) issued its quarterly earnings results on Monday. The company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.03). Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.March 18, 2025 | marketbeat.comGyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $24,620.00 in StockGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the company's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $12.31, for a total value of $24,620.00. Following the completion of the transaction, the president now directly owns 2,831,260 shares of the company's stock, valued at approximately $34,852,810.60. The trade was a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.March 18, 2025 | marketbeat.comGyre Therapeutics reports Q4 EPS 0c vs. ($1.39) last yearMarch 18, 2025 | markets.businessinsider.comGyre Therapeutics (GYRE) Projected to Post Earnings on TuesdayGyre Therapeutics (NASDAQ:GYRE) will be releasing earnings before the market opens on Tuesday, March 25, Financial Modeling Prep reports.March 18, 2025 | marketbeat.comGyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 17, 2025 | globenewswire.comGyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $23,480.00 in StockGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $11.74, for a total transaction of $23,480.00. Following the completion of the sale, the president now directly owns 2,835,260 shares of the company's stock, valued at $33,285,952.40. The trade was a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.March 14, 2025 | marketbeat.comFY2024 Earnings Estimate for GYRE Issued By Noble FinancialGyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) - Noble Financial issued their FY2024 earnings per share (EPS) estimates for shares of Gyre Therapeutics in a report issued on Tuesday, March 11th. Noble Financial analyst R. Leboyer expects that the company will post earnings per share of $0.17March 14, 2025 | marketbeat.comGyre Therapeutics initiated with an Outperform at Noble CapitalMarch 13, 2025 | markets.businessinsider.comInsider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of StockGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $10.14, for a total value of $20,280.00. Following the sale, the president now owns 2,839,260 shares in the company, valued at $28,790,096.40. The trade was a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.March 12, 2025 | marketbeat.comGyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $20,500.00 in StockGyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $10.25, for a total value of $20,500.00. Following the sale, the president now directly owns 2,841,260 shares of the company's stock, valued at approximately $29,122,915. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.March 12, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Up 13.9% - Here's What HappenedGyre Therapeutics (NASDAQ:GYRE) Shares Up 13.9% - Time to Buy?March 12, 2025 | marketbeat.comExploring High Growth Tech Stocks In The US March 2025March 12, 2025 | finance.yahoo.comNoble Financial Initiates Coverage on Gyre Therapeutics (NASDAQ:GYRE)Noble Financial assumed coverage on Gyre Therapeutics in a research report on Tuesday. They set an "outperform" rating on the stock.March 12, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading Volume - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Sees Large Volume Increase - Time to Buy?March 11, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - Should You Buy?March 8, 2025 | marketbeat.comSBI Securities Co. Ltd. Acquires Shares of 101,239 Gyre Therapeutics, Inc. (NASDAQ:GYRE)SBI Securities Co. Ltd. bought a new position in Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 101,239 shares of the company's stock, valued at approximately $1,March 4, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Up 7.6% - Here's WhyGyre Therapeutics (NASDAQ:GYRE) Stock Price Up 7.6% - Here's WhyFebruary 25, 2025 | marketbeat.comGyre Therapeutics (NASDAQ:GYRE) Trading Down 9.1% - Should You Sell?Gyre Therapeutics (NASDAQ:GYRE) Trading Down 9.1% - Should You Sell?February 24, 2025 | marketbeat.comGyre Therapeutics Faces Revenue Decline Amidst Future ProspectsFebruary 18, 2025 | tipranks.comGyre therapeutics president Ma Songjiang sells $46,360 in stockFebruary 14, 2025 | msn.com Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address GYRE Media Mentions By Week GYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GYRE News Sentiment▼0.480.66▲Average Medical News Sentiment GYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GYRE Articles This Week▼22▲GYRE Articles Average Week Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cytokinetics News Today Krystal Biotech News Today Rhythm Pharmaceuticals News Today PTC Therapeutics News Today Sarepta Therapeutics News Today Avidity Biosciences News Today SpringWorks Therapeutics News Today Ultragenyx Pharmaceutical News Today Akero Therapeutics News Today Arcellx News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GYRE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GYRE Stock Free GYRE Stock Alerts